A UK biotech launched in 2023 to use protein degradation technology to develop new drugs for neurodegenerative diseases has raised $31 million in seed funding from a selection of UK and US investors. The company, TRIMTECH Therapeutics Ltd, has a pipeline of small molecule candidate therapies for disorders including Alzheimer’s and Huntington’s diseases. The drugs are intended to target the body’s ubiquitin-proteasome system to mark proteins for degradation. The proteins are toxic aggregates associated with a range of neurodegenerative and inflammatory disorders.
Announced on 5 March, the seed funding round was led by two of the company’s founders, Cambridge Innovation Capital and SV Health Investor’s Dementia Discovery Fund. They were supported by M Ventures and Pfizer Ventures. Other investors included Eli Lilly and Co, MP Healthcare Venture Management, and Cambridge Enterprise Ventures. In a statement, Nicola Thompson, the company’s chief executive, said the company’s goal is to remove aggregated proteins in the body that underpin many diseases of the central nervous system. A September 2024 article in the journal Cell Chemical Biology said that small molecule protein degraders are designed to target and remove pathogenic proteins from central nervous system cells without encountering the delivery problems associated with antibody therapeutics.
Copyright 2025 Evernow Publishing Ltd